Results 281 to 290 of about 47,200 (309)

Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation

Annals of Internal Medicine, 2020
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau, C. Cheung, Kenneth K C Man, E. Chan, C. Sing, G. Lip, C. Siu, J. Lam, A. Lee, I. Wong   +9 more
semanticscholar   +1 more source

Gastrointestinal disorders and dabigatran

Scandinavian Journal of Gastroenterology, 2012
Anticoagulants play an important role in the prevention and treatment of a variety of acute and chronic thromboembolic disorders such as primary prevention and treatment of venous thromboembolism or prevention of stroke and systemic embolism in atrial fibrillation just to name of few.
Arthur Hoffman, Peter R. Galle
openaire   +3 more sources

Idarucizumab for dabigatran overdose

Clinical Toxicology, 2016
An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Laurens Liesenborghs, Paul A. Reilly, Marijke Peetermans, Charles V. Pollack, Peter Verhamme, Jeffrey I. Weitz, Jerrold H. Levy, Marc Jacquemin   +7 more
openaire   +3 more sources

Dabigatran: A Primer for Neurosurgeons

World Neurosurgery, 2013
This study sought to present an overview of dabigatran, a new anticoagulant, and to discuss the implications for the perioperative management of patients taking dabigatran.We reviewed the English literature pertaining to the new oral anticoagulant, dabigatran (Pradaxa).Dabigatran has the advantage of providing rapid and steady anticoagulation without ...
Jennifer E. Fugate, Giuseppe Lanzino, Robert D. McBane, Alejandro A. Rabinstein   +3 more
openaire   +3 more sources

Dabigatran as an oral anticoagulant in patients with Budd–Chiari syndrome post‐percutaneous endovascular intervention

Journal of Gastroenterology and Hepatology, 2020
Anticoagulants play an important role in the management of Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting oral anticoagulants—dabigatran, among patients with Budd–Chiari syndrome.
Sanchit Sharma, Ramesh Kumar, Gyanranjan Rout, S. Gamanagatti, R. Shalimar   +4 more
semanticscholar   +1 more source

Use of dabigatran with antiretrovirals

HIV Medicine, 2019
ObjectivesTheoretical and untested interactions between antiretrovirals and direct‐acting oral anticoagulants have limited the use of this new class of anticoagulant in people with HIV infection. This case series, the first of its kind, reports on the successful concurrent use of the direct‐acting oral anticoagulant dabigatran and antiretroviral ...
J Perram, E O'Dwyer, C Holloway
openaire   +3 more sources

Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease

Drug Metabolism and Personalized Therapy, 2020
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
D. Sychev, A. Skripka, Kristina Ryzhikova, P. Bochkov, R. Shevchenko, P. Krupenin, D. Ivashchenko, V. Kogay, A. Listratov, A. Krainyaya, O. Gurinovich, A. Sokolova, D. Napalkov, V. Fomin   +13 more
semanticscholar   +1 more source

Removal of Dabigatran by Hemodialysis

American Journal of Kidney Diseases, 2013
Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that invasive laboratory testing and dose adjustment is not necessary.
Don N. Chang, William E. Dager, Andrew I. Chin   +2 more
openaire   +3 more sources

Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke

Stroke, 2020
Supplemental Digital Content is available in the text. Background and Purpose— Reversal of dabigatran before intravenous thrombolysis in patients with acute ischemic stroke has been well described using alteplase but experience with intravenous ...
J. Beharry, M. Waters, R. Drew, J. Fink, D. Wilson, B. Campbell, M. Parsons, T. Kleinig, Teddy Y. Wu   +8 more
semanticscholar   +1 more source

Reversal of Dabigatran with Idarucizumab

Expert Review of Cardiovascular Therapy, 2016
The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R. Sodha, Frank W. Sellke
openaire   +3 more sources